Annuncio pubblicitario
Italia markets open in 7 hours 41 minutes
  • Dow Jones

    38.989,83
    -97,55 (-0,25%)
     
  • Nasdaq

    16.207,51
    -67,43 (-0,41%)
     
  • Nikkei 225

    40.109,23
    0,00 (0,00%)
     
  • EUR/USD

    1,0857
    -0,0002 (-0,02%)
     
  • Bitcoin EUR

    62.976,32
    +4.564,54 (+7,81%)
     
  • CMC Crypto 200

    885,54
    0,00 (0,00%)
     
  • HANG SENG

    16.595,97
    +6,53 (+0,04%)
     
  • S&P 500

    5.130,95
    -6,13 (-0,12%)
     

Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023

Orion Oyj
Orion Oyj

ORION CORPORATION
PRESS RELEASE
16 October 2023 at 12.15 EEST

Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023

Orion will publish Interim Report for January–September 2023 on Thursday, 26 October 2023 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Thursday, 26 October 2023 at 13.30 EEST.

A link to the live webcast is available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link:
http://palvelu.flik.fi/teleconference/?id=1009428

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.